ClinicalTrials.gg
RecruitingNCT06656533TREATUpdated Apr 23, 2026

Optimizing the Timing of rTMS to Enhance the Administration of Insomnia Treatment

An interventional study of Repeated Transcranial magnetic stimulation (rTMS) in Insomnia, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 25 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Stanford University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
25 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Sleep Initiation and Maintenance Disorders by Stanford University — 2 open to participants now, 2 under way, none of them phase 3. Sleep Initiation and Maintenance Disorders · Stanford University.

Planned enrollment
22nd of 22
10 · median 68
Started
2025
the only one that year
No phase
16 of 22
2 open now
Registered
22nd of 22
by date

Among the 22 studies in Sleep Initiation and Maintenance Disorders by Stanford University, this one is the 22nd largest by planned enrollment, is the only one that started in 2025, is one of 16 with no phase, and was the 22nd registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

2 of the 22 studies in Sleep Initiation and Maintenance Disorders by Stanford University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 25 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Sleep Initiation and Maintenance Disorders by Stanford University, or all of them as a file.
02

Study summary

Repetitive transcranial magnetic stimulation (rTMS) has shown to be a promising technique for improving insomnia symptoms and sleep quality. However, the impact of circadian rhythmicity on rTMS sessions and its potential influence on insomnia therapy remains unclear. Moreover, the effect of rTMS on objective sleep parameters is not fully established. The objective of this pilot study is to establish key feasibility and preliminary data that would be used for an R-level grant application focused on optimizing rTMS therapy for insomnia. The investigators will acquire feasibility data from ten adults with Insomnia disorder. Participants will receive ten sessions rTMS over two weeks, either in the morning or evening. Sleep parameters will be assessed before, during, and after completion of rTMS and brain cortical excitability will be collected before rTMS treatment. The investigators aim to 1) evaluate the impact of circadian timing of rTMS sessions on subjective and objective sleep outcomes, 2) assess the time course of improvements in sleep outcomes, and 3) examine the association between sleep outcomes and cortical excitability. The overarching goal of this work is to optimize rTMS therapy for insomnia by investigating the impact of circadian timing on rTMS sessions and assessing potential variations in subjective and objective measures of sleep.

Read the detailed description

Low frequency (1 Hz) rTMS has shown promise to reduce cortical hyperexcitability and to improve subjective measures of sleep quality and insomnia symptoms in patients with insomnia disorder (ID) (Nardone et al. 2020). However, the few studies to date that have examined the objective measures of sleep parameters using Polysomnography (PSG), have yielded heterogeneous results. The variability in the PSG measures of sleep may potentially be attributed to the effectiveness of rTMS therapy delivered at different times of day because of changes in cortical excitability related across the 24-hour period (Ly et al. 2016) as well as the temporal proximity of the stimulation to sleep. However, the impact of the timing of rTMS administration on improving insomnia has not yet been examined. In this pilot study, the investigators aim to demonstrate the feasibility of the data acquisition using the proposed protocol and to establish preliminary data that would be used in a future R-level grant. Building on this preliminary data, the future R-level grant would be focused on optimizing rTMS therapy for insomnia and sleep quality by manipulating the time of day that the rTMS sessions are delivered. In the following, the investigators will provide their aims for this pilot study.

The investigators' objectives are 1. To assess the impact of morning versus evening administration of rTMS on a) subjective and b) objective sleep outcomes. Here the investigators propose to enroll 10 participants and randomize each to either receive 10 sessions of rTMS over two weeks in the morning or in the evening. This pilot study would provide preliminary time-of-day effects on subjective (sleep diary parameters and insomnia severity) and objective sleep (wristwatch actigraphy and PSG) measures. It characterizes the time course of improvement across the two-week treatment period for a) subjective and b) objective sleep measures. Throughout the multi-week intervention, the investigators will collect subjective and objective sleep measures to characterize the improvement across the two-week period.

Finally, this pilot study would determine whether cortical excitability predicts treatment outcomes. Participants will undergo a TMS-EEG session before rTMS therapy. Cortical excitability will be assessed by measuring TMS-evoked EEG potentials (TEP).

03

Conditions studied

  • Insomnia

Keywords

  • Sleep
  • Insomnia
  • rTMS Therapy
04

Who can participate

Ages eligible
25 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females of any racial or ethnic group, aged 25-45 (inclusive)
  • Insomnia diagnosis via the DUKE
  • Fluent and literate in English
  • Written,
  • Reside within 60 miles of Stanford University

Exclusion criteria

Exclusion Criteria:

  • Presence of other sleep or circadian rhythm disorders that significantly contribute to their sleep disturbance. The presence of these disorders will be assessed by the DUKE structured interview for sleep disorders.
  • No regular use of benzodiazepine, opiate, thyroid, anticonvulsant or antipsychotic medications
  • Use of psychotropic medications that would significantly impact sleep, alertness, and no illicit drugs.
  • Excessive alcohol consumption (>14 drinks per week or > 4 drinks per occasion)
  • Presence of suicidal ideations representing elevated risk as determined by the Beck Depression Inventory (score of > 0 on BDI question #9).
  • History of neurological or cardiovascular disorders, brain surgery, electroconvulsive or radiation treatment, brain hemorrhage or tumor, stroke, seizures or epilepsy, diabetes, hypo- or hyperthyroidism, head trauma with loss of consciousness greater than thirty minutes.
  • Substance abuse or dependence
  • History of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities OR traumatic brain injury in the past two months
  • Severe impediment to vision, hearing and/or hand movement, likely to interfere with the ability to complete the assessments, or are unable and/or unlikely to follow the study protocols
  • Pregnant or breast feeding
  • Current or lifetime history of bipolar disorder, PTSD or psychosis or current depression
  • Received cognitive behavioral therapy for insomnia within the past year
  • Current exposure to trauma, or exposure to trauma within the past 3 months
  • Working a rotating shift that overlaps with 2400h
  • Individuals who were high risk for sleep apnea on the Berlin Questionnaire and are not CPAP adherent
  • Participants with a current psychiatric disorder who are also on medications that significantly increase the risk of seizure. The antidepressants clomipramine, bupropion, maprotiline will be excluded because they are known to increase risk of up to 0.5-2.2% from a population reference range of 0.07- 0.08% in the general population and 0.1-4% in the population of people taking antidepressants.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    MORNING GROUP

    Five participants (21 to 45 years old) experiencing clinically meaningful insomnia symptoms will be enrolled and will receive 10 sessions of right dorsolateral prefrontal cortex (DLPFC) rTMS therapy in the morning over two consecutive weeks.

    Other: Repeated Transcranial magnetic stimulation (rTMS)

  • Experimental
    EVENING GROUP

    Five participants (21 to 45 years old) experiencing clinically meaningful insomnia symptoms will be enrolled and will receive 10 sessions of right dorsolateral prefrontal cortex (DLPFC) rTMS therapy in the evening over two consecutive weeks.

    Other: Repeated Transcranial magnetic stimulation (rTMS)

Interventions

  • OtherRepeated Transcranial magnetic stimulation (rTMS)

    Transcranial Magnetic Stimulation (TMS) involves a procedure where parts of the participants brain will be non-invasively (i.e. indirectly) stimulated by magnetic pulses. These magnetic pulses induce very brief activity in brain areas underlying the TMS coil. TMS will be performed by giving repetitive pulses (rTMS). rTMS has shown promise to reduce cortical hyperexcitability and to improve subjective measures of sleep quality and insomnia symptoms in patients with insomnia disorder. The goal of this study is to optimize the impact of rTMS therapy on sleep outcomes for patients with insomnia disorder.

06

What researchers measure

Primary outcomes

  1. Insomnia Severity Index (ISI)

    Improvement in insomnia symptoms will be assessed using the Insomnia Severity Index (ISI). ISI is a 7-item self-report questionnaire designed to assess the severity of insomnia symptoms and their impact on daily functioning. Each question is scored on a 5-point Likert scale, with ratings from 0 (no problem) to 4 (very severe problem).

    Time frame: Insomnia severity index will be collected within one week before and within one week after the 10 sessions (over two weeks) of rTMS therapy.

  2. Pittsburgh Sleep Quality Index

    Improvement in subjective sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). PSQI is a widely used questionnaire that assesses sleep quality and disturbances over one month. It includes seven components and ranges from 0 to 21, with higher scores indicating poorer sleep quality. A score above 5 is generally considered indicative of poor sleep quality.

    Time frame: Pittsburgh Sleep Quality Index will be collected within one week before and within one week after the 10 sessions (over two weeks) of rTMS therapy.

Secondary outcomes

  1. OBJECTIVE SLEEP MEASURES

    Changes in sleep parameters, objectively measured using an Electroencephalogram (EEG) and Actiwatch, will be assessed following rTMS therapy. Sleep Efficiency (the percentage of time a person spends asleep compared to the total amount of time they spend in bed), Wake After Sleep Onset (the amount of time a person is awake after falling asleep but before waking up for the day), and Sleep Latency ( the amount of time it takes to fall asleep after turning off the lights) will be calculated from EEG and Actiwatches. Additionally, sleep architecture including time spent in sleep stages and spectral measures will be collected using EEG.

    Time frame: EEG sleep parameters will be collected within one week before and within one week after 10 sessions (over two weeks)of rTMS therapy. Actiwatch sleep measures will be collected from one week before the baseline session to the end of the treatment session.

  2. Cortical Excitability

    Cortical excitability, defined as the strength of cortical neural responses to stimulations, will be assessed by measuring TMS-evoked EEG potentials (TEP). Specifically, the amplitude of the change in EEG data after a single TMS pulse in the supplementary motor area will be quantified and associated with changes in sleep measures and insomnia severity index.

    Time frame: Cortical excitability will be measured during the first therapy session, before the first rTMS therapy.

07

Study locations

1 of 1 sites recruiting
  • 1070 Arastradero Road
    Palo Alto, California 94304, United States
    Recruiting
    • Maryam Ahmadi, PhD · Contactahmadi1@stanford.edu · 951-231-3891
    • Andrea Goldstein Piekarski, PhD · Principal investigator
08

References and documents

Publications

  • Ly JQM, Gaggioni G, Chellappa SL, Papachilleos S, Brzozowski A, Borsu C, Rosanova M, Sarasso S, Middleton B, Luxen A, Archer SN, Phillips C, Dijk DJ, Maquet P, Massimini M, Vandewalle G. Circadian regulation of human cortical excitability. Nat Commun. 2016 Jun 24;7:11828. doi: 10.1038/ncomms11828. PubMed 27339884 ↗
  • Nardone R, Sebastianelli L, Versace V, Brigo F, Golaszewski S, Pucks-Faes E, Saltuari L, Trinka E. Effects of repetitive transcranial magnetic stimulation in subjects with sleep disorders. Sleep Med. 2020 Jul;71:113-121. doi: 10.1016/j.sleep.2020.01.028. Epub 2020 Feb 19. PubMed 32173186 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Sep 2026, 18 months after the start.

Of 1,219 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 18 months is above that.

Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2024
First posted
Oct 24, 2024
StartActual
Mar 1, 2025
Primary completionEst.
Sep 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06656533
Responsible party
Andrea Goldstein-Piekarski (ASSISTANT PROFESSOR, Stanford University) — Principal investigator
First posted
Oct 24, 2024
Start date
Mar 1, 2025
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Apr 23, 2026

Study contacts

Maryam Ahmadi, PhD
Contact
maryamahmadi529@gmail.com
9512313891
Andrea Goldstein Piekarski, PhD
Contact
agoldpie@stanford.edu

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion